National Research Corporation (NRC Health) has announced its financial results for the second quarter of 2025, highlighting a 2% sequential growth in Total Recurring Contract Value (TRCV). This marks the third consecutive quarter of TRCV growth and represents the highest sequential growth rate since the first quarter of 2021. CEO Trent S. Green expressed optimism about the company's continued momentum and customer enthusiasm for NRC Health's product portfolio. During the second quarter, NRC repurchased 381,736 shares at a weighted average price of $14.96 per share. In 2025, the company has returned a total of $16.1 million to shareholders through dividends and stock repurchases. The company's adjusted EBITDA margin was reported at 30% for the quarter, maintaining stability over the past year due to cost control initiatives and increased revenue per FTE. However, net margin stood at 0% for the quarter due to non-recurring cash bonuses and equity grants related to executive compensation arrangements following the transition from founder-led leadership. NRC Health also declared a quarterly cash dividend of $0.12 per share, payable on October 10, 2025, to shareholders of record as of September 26, 2025.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。